70 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
PFE Pfizer, Inc. $43.01 $252.13B Buy
Article Searches
Exact Sciences Hit a Home Run in Q4. Here's Why Sales Could Soon Soar Even More. https://www.fool.com/investing/2019/02/24/exact-sciences-hit-a-home-run-in-q4-heres-why-sale.aspx?source=iedfolrf0000001 Feb 24, 2019 - If you liked Exact Sciences' latest quarterly results, you'll probably love what could be in store.
Congress Grills Drugmakers: 5 Key Takeaways https://www.fool.com/investing/2019/02/26/congress-grills-drugmakers-5-key-takeaways.aspx?source=iedfolrf0000001 Feb 26, 2019 - Top drug companies addressed sky-high drug prices on Capitol Hill today.
Can This Biotech Puppy Run With the Big Dogs? https://www.fool.com/investing/2019/03/04/can-this-biotech-puppy-run-with-the-big-dogs.aspx?source=iedfolrf0000001 Mar 04, 2019 - Pfizer and Alnylam have a fierce, young contender with a chance to catch up in a big way.
Lilly's Cyramza Successful in Phase III First-Line NSCLC Study http://www.zacks.com/stock/news/359294/lillys-cyramza-successful-in-phase-iii-first-line-nsclc-study?cid=CS-ZC-FT-359294 Mar 13, 2019 - Lilly's (LLY) cancer drug, Cyramza, in combination with erlotinib significantly delays disease progression in a phase III study on previously untreated patients with EGFR-mutated metastatic NSCLC.
Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma http://www.zacks.com/stock/news/359301/aerie-aeri-receives-fda-nod-for-rocklatan-to-treat-glaucoma?cid=CS-ZC-FT-359301 Mar 13, 2019 - Aerie (AERI) gets FDA approval for Rocklatan to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension and announces its 2019 revenue and cash burn outlook.
Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others http://www.zacks.com/stock/news/359854/pharma-stock-roundup-regulatory-updates-from-mrk-pfe-jj-agn-others?cid=CS-ZC-FT-359854 Mar 15, 2019 - Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.
Allergan's Anti-Infective Gets FDA Nod for Pediatric Patients http://www.zacks.com/stock/news/361445/allergans-anti-infective-gets-fda-nod-for-pediatric-patients?cid=CS-ZC-FT-361445 Mar 19, 2019 - The FDA approves Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.
Aerie (AERI) Starts Phase II Study on Eye Candidate AR-1105 http://www.zacks.com/stock/news/361538/aerie-aeri-starts-phase-ii-study-on-eye-candidate-ar-1105?cid=CS-ZC-FT-361538 Mar 19, 2019 - Aerie (AERI) begins dosing in a phase II study on AR-1105 for treating patients with macular edema due to retinal vein occlusion.
Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan http://www.zacks.com/stock/news/363393/aerie-aeri-starts-phase-ii-study-on-eye-candidate-in-japan?cid=CS-ZC-FT-363393 Mar 22, 2019 - Aerie (AERI) begins dosing in a phase II study on netarsudil ophthalmic solution in Japan for curbing high intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Shares Up.
Top Research Reports for Pfizer, Royal Dutch Shell & Celgene http://www.zacks.com/research-daily/370129/top-research-reports-for-pfizer-royal-dutch-shell-celgene?cid=CS-ZC-FT-370129 Apr 03, 2019 - Top Research Reports for Pfizer, Royal Dutch Shell & Celgene

Pages: 1234567

Page 1>